The inhalation therapy Tyvaso (treprostinil) significantly improved a measure of lung function for people with idiopathic pulmonary fibrosis (IPF) in a Phase 3 clinical trial. The top-line result means that the Phase 3 TETON 2 clinical trial (NCT05255991) has met its main goal. Tyvaso’s developer, United Therapeutics, plans to use findings from the study and […] The post Tyvaso boosts lung function in IPF trial, per top-line data appeared first on Pulmonary Fibrosis News.
